Adaptive Biotechnologies (NASDAQ:ADPT) Shares Up 9.3% – What’s Next?

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shares shot up 9.3% on Thursday . The stock traded as high as $18.49 and last traded at $18.6650. 994,640 shares traded hands during mid-day trading, a decline of 49% from the average session volume of 1,938,534 shares. The stock had previously closed at $17.07.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ADPT. Guggenheim reiterated a “buy” rating and issued a $21.00 target price on shares of Adaptive Biotechnologies in a report on Wednesday, May 6th. BTIG Research reiterated a “buy” rating and issued a $22.00 target price on shares of Adaptive Biotechnologies in a report on Wednesday, May 6th. TD Cowen increased their target price on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Wall Street Zen lowered shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Finally, Morgan Stanley lowered their price objective on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $19.57.

Adaptive Biotechnologies Price Performance

The company’s 50-day moving average price is $14.57 and its 200-day moving average price is $15.68. The company has a market cap of $2.82 billion, a P/E ratio of -53.33 and a beta of 2.15.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The company had revenue of $70.87 million during the quarter, compared to the consensus estimate of $61.03 million. During the same quarter in the prior year, the firm earned ($0.20) earnings per share. The firm’s revenue was up 35.1% compared to the same quarter last year. On average, equities research analysts predict that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Insider Activity at Adaptive Biotechnologies

In related news, COO Julie Rubinstein sold 30,941 shares of the firm’s stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $14.83, for a total value of $458,855.03. Following the completion of the transaction, the chief operating officer owned 434,188 shares of the company’s stock, valued at approximately $6,439,008.04. This trade represents a 6.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chad M. Robins sold 83,332 shares of the firm’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $14.41, for a total transaction of $1,200,814.12. Following the completion of the transaction, the chief executive officer directly owned 2,217,781 shares of the company’s stock, valued at approximately $31,958,224.21. This trade represents a 3.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 516,654 shares of company stock valued at $7,509,691. Corporate insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd bought a new position in Adaptive Biotechnologies in the fourth quarter valued at $28,000. EverSource Wealth Advisors LLC grew its position in Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after purchasing an additional 1,565 shares in the last quarter. KBC Group NV bought a new position in Adaptive Biotechnologies in the first quarter valued at $45,000. Assetmark Inc. grew its position in Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after purchasing an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new position in Adaptive Biotechnologies in the fourth quarter valued at $51,000. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.